newswire, breaking biotechnology and pharma news

Thursday, October 14, 2010 - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference - Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference

LINCOLNSHIRE, Ill. - October 14, 2010 ( newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.

Stephen M. Simes, BioSante's president & chief executive officer, will speak at 11:00 am EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials, as well as comment on the receipt of FDA orphan drug designation received for several of the cancer vaccines.

The agenda for the Cancer Immunotherapy: A Long Awaited Reality conference includes keynotes and plenary discussions, roundtable lunch conversations with experts, a focused science and industry track, as well as networking opportunities. The conference will be hosted by MD Becker Partners and BioBusiness.TV. There will be a corresponding live webcast of the conference, which can be accessed by visiting Jill O'Donnell-Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), is scheduled to present a keynote address titled "The Future of Cancer Vaccine Development."

About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at:

About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. In early April 2010, MD Becker Partners published a 150-page industry report titled "Cancer Vaccine Therapies: Failures and Future Opportunities," which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discussion of the scientific, clinical, and commercial considerations for major industry participants. For more information visit

About BioBusiness.TV
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. For more information, visit

BioSante Pharmaceuticals
For Media:The Trout Group LLCTricia Swanson(646)
For Investors:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316

Visit the BPAX showcase profile at -
Request News and Info on BPAX -

Visit this company:
Disclosure, Disclaimer: BPAX is a paid advertising client on

Published at - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with - Publish Your News - Send a release -

Disclaimer: The following news is paid for and /or published as information only for our readers. is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:

No comments:

Post a Comment